- Home
- SRPT vs NCLH Comparison
SRPT vs NCLH Comparison
Compare SRPT & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRPT
- NCLH
- Stock Information
- Founded
- SRPT 1980
- NCLH 1966
- Country
- SRPT United States
- NCLH United States
- Employees
- SRPT N/A
- NCLH N/A
- Industry
- SRPT Biotechnology: Pharmaceutical Preparations
- NCLH Marine Transportation
- Sector
- SRPT Health Care
- NCLH Consumer Discretionary
- Exchange
- SRPT Nasdaq
- NCLH Nasdaq
- Market Cap
- SRPT 12.2B
- NCLH 12.1B
- IPO Year
- SRPT 1997
- NCLH 2013
- Fundamental
- Price
- SRPT $120.39
- NCLH $26.29
- Analyst Decision
- SRPT Buy
- NCLH Buy
- Analyst Count
- SRPT 21
- NCLH 16
- Target Price
- SRPT $179.38
- NCLH $29.27
- AVG Volume (30 Days)
- SRPT 1.0M
- NCLH 9.2M
- Earning Date
- SRPT 11-06-2024
- NCLH 10-31-2024
- Dividend Yield
- SRPT N/A
- NCLH N/A
- EPS Growth
- SRPT N/A
- NCLH N/A
- EPS
- SRPT 1.22
- NCLH 1.25
- Revenue
- SRPT $1,640,348,000.00
- NCLH $9,356,741,000.00
- Revenue This Year
- SRPT $50.40
- NCLH $13.10
- Revenue Next Year
- SRPT $71.44
- NCLH $8.05
- P/E Ratio
- SRPT $103.94
- NCLH $21.10
- Revenue Growth
- SRPT 48.45
- NCLH 15.76
- 52 Week Low
- SRPT $89.92
- NCLH $14.69
- 52 Week High
- SRPT $173.25
- NCLH $28.64
- Technical
- Relative Strength Index (RSI)
- SRPT 50.01
- NCLH 50.77
- Support Level
- SRPT $122.12
- NCLH $26.15
- Resistance Level
- SRPT $128.73
- NCLH $27.63
- Average True Range (ATR)
- SRPT 3.87
- NCLH 0.91
- MACD
- SRPT -0.15
- NCLH -0.21
- Stochastic Oscillator
- SRPT 11.14
- NCLH 25.55
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 66,500). It operates 32 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 41,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.